Judges Scientific stages rapid turnaround

By dint of its business model, growth prospects for Judges Scientific (JDG) will always be bound up with a buy-and-build strategy. But a 14 per cent rise in organic revenue at the half-year mark demonstrates that the latter part of the formula isn’t being overlooked. Essentially, the group acquires and adds value to scientific instrument businesses. But the nature of the business, not dissimilar to that of private equity firms, means that earnings progression is rarely linear.